We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drugmakers Report Zoloft Shortage Amid COVID-19

Drugmakers Report Zoloft Shortage Amid COVID-19

June 3, 2020

Makers of Zoloft (sertraline hydrochloride) and its generic versions are reporting shortages linked to increased demand during the pandemic coupled with supply chain issues caused by the impact of COVID-19 on manufacturers of active pharmaceutical ingredients (APIs).

Accord Healthcare, InvaGen Pharmaceuticals, Lupin and Pfizer, the blockbuster antidepressant’s brand name manufacturer, have all reported to the FDA that they are experiencing difficulties in supplying the product.

The FDA said it is working closely with the drugmakers on increasing their supply to respond to the increased demand. An agency spokesperson noted that there have been previous shortages of antidepressants, but that Zoloft and generic sertraline have not been in shortage in recent years.

Pfizer has noted shortages for two of its Zoloft packages, estimating that one would be resolved this month while the timeline for the other is yet to be determined.

“We are able to supply our historical market share but unable to make up for increased demand,” a Pfizer spokesperson said.

Two other versions of the product that were in shortage — which were not detailed on the FDA’s drug shortages database — are now back in stock, a Pfizer spokesperson said.

For Accord and Lupin, the problems stem from a struggle to obtain the active pharmaceutical ingredient (API) needed to make their generic versions. Citing the impact of COVID-19, Accord said that it is currently unable to support monthly demand for three versions of its generic, including its 500-count 50mg and 100mg versions, because it can’t obtain the API. That shortage is expected to last 60 days.

Similarly, Lupin said it is facing an API shortage and increased demand, leaving it unable to adequately supply 11 versions of its generic. Although it’s engaging in continuous production, the drugmaker said the products will be on back order for a “few months.”

InvaGen, a subsidiary of Cipla, said seven versions of its generic sertraline are on back order, but did not give reasons for the shortages. — James Miessler

COVID-19

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing